Principal Investigator - Dr. Scott Dryden-Peterson MD, MSc

Study Objectives

Aim 1: The study will compare the LVEF between patients with and without HIV  who are being treated with anthracyclines. We hypothesize that the LVEF will be  lower after anthracycline among individuals living with HIV.

Aim 2: In a mechanistic study, we will compare the increase in myocardial fibrosis  after anthracyclines between individuals living with HIV and uninfected controls.  We hypothesize that that HIV status will be associated with a greater increase in fibrosis after anthracyclines.  

Study Design

The study is a prospective observational cohort study where study subjects will undergo a cardiac magnetic resonance (CMR) study at baseline prior to chemotherapy and at 12 months after chemotherapy.

Study population: Total sample size is 25. These will be recruited from Botswana Prospective Cancer Cohort in Gaborone. This includes the Princess Marina Hospital, Bokamoso Private Hospital, and Gaborone Private Hospital. 

  • Adults (≥18 years of age) scheduled to start anthracycline-based chemotherapy

Study duration: 5 years 

Sponsor: National Institutes of Health- National Cancer Institute (HIH-NCI).

Study Findings



Contact Details